SynthesisReproductive biology and endocrinology : RB&E2021
Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Reproductive biology and endocrinology : RB&E, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07691073 (The Impact of Ovarian Stimulation With hMG on Embryo Quality in Advanced Age Women. A Randomized Controlled Trial), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of Ovarian Stimulation With hMG on Embryo Quality in Advanced Age Women. A Randomized Controlled Trial
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025†.Human reproduction (Oxford, England) · 2026Guideline
- Comparative Effectiveness of Recombinant Human Follicle-Stimulating Hormone:Recombinant Human Luteinizing Hormone in a 2:1 Ratio versus Highly Purified Human Menopausal Gonadotropin Alone in Ovarian Stimulation for Medically Assisted Reproduction Treatment Using in vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review and Meta-Analysis.Gynecologic and obstetric investigation · 2026Pooled it
- Luteinizing hormone activity in ovarian stimulation: comparative efficacy and safety of gonadotropinsFrontiers in endocrinology · 2026Pooled it
- Recombinant LH supplementation during ovarian stimulation modulates early embryo morphokinetics without affecting IVF outcomes in normal responders: a retrospective time-lapse study.Journal of assisted reproduction and genetics · 2026Article
- Does the type of gonadotropin used in the index IVF cycle affect subsequent frozen embryo transfer outcomes? Results of a retrospective analysis.Journal of assisted reproduction and genetics · 2026Article
- Letrozole Co-Administration in Progestin-Primed Ovarian Stimulation (PPOS) Protocols for Patients Undergoing In Vitro Fertilization: A Systematic Review.Journal of clinical medicine · 2026Review
- Optimizing family building in women of advanced reproductive age: a Faster-Fewer-and-Finished approach.Frontiers in endocrinology · 2026Review
- Impact of adding r-LH to r-FSH during ovarian stimulation on reproductive outcomes of women with polyendocrine metabolic ovarian syndrome undergoingFrontiers in endocrinology · 2026Article
- Luteinizing hormone supplementation and cumulative live birth rate in assisted reproductive technology cycles among women of advanced reproductive age.Frontiers in endocrinology · 2026Article
- The role of luteinizing hormone in the management of female infertility: A French Delphi consensus.Journal of assisted reproduction and genetics · 2025Article
- Introduction: luteinizing hormone for life's journey.Reproductive biology and endocrinology : RB&E · 2025Article
- The role of recombinant LH in ovarian stimulation: what's new?Reproductive biology and endocrinology : RB&E · 2025Review
- Pharmacogenomic of LH and its receptor: are we ready for clinical practice?Reproductive biology and endocrinology : RB&E · 2025Review
- Surfing follicular waves in ovarian stimulation: is there a role for LH in DuoStim protocols? A narrative review and SWOT analysis.Reproductive biology and endocrinology : RB&E · 2025Review
- The role of LH in follicle development: from physiology to new clinical implications.Reproductive biology and endocrinology : RB&E · 2025Review
- Management of LH/FSH deficiency among assisted reproduction specialists in Spain: a Delphi consensus.Frontiers in endocrinology · 2025Article
- Associations between serum 25- hydroxyvitamin D concentrations and assisted reproductive technology outcomes in women with polycystic ovary syndrome: a cohort study.Frontiers in endocrinology · 2025Article
- The influence of the pharmaceutical industry on the development of gonadotrophins and ovarian stimulation protocols in assisted reproductive technologies.Frontiers in endocrinology · 2025Review
- Recombinant Follicle-Stimulating Hormone and Luteinizing Hormone Enhance Mitochondrial Function and Metabolism in Aging Female Reproductive Cells.International journal of molecular sciences · 2024Article
- Patients with low prognosis in ART: a Delphi consensus to identify potential clinical implications and measure the impact of POSEIDON criteria.Reproductive biology and endocrinology : RB&E · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral studies suggest that luteinizing hormone (LH) could improve IVF outcome in women of advanced reproductive age by optimizing androgen production. In this review, we assessed the role of recombinant-human LH (r-hLH) and recombinant human follicle stimulating hormone (r-hFSH) co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age candidates for assisted reproduction. MATERIAL AND
methodsUsing a preregistered protocol we systematically searched Medline/PubMed, Scopus and the ISI Web of Science databases to identify randomized controlled trials in which r-hFSH monotherapy protocols were compared with r-hFSH/r-hLH co-treatment in women ≥35 years undergoing fresh IVF cycles. We calculated the pooled odds ratio (OR) for dichotomous data and the weight mean difference (WMD) for continuous data with an associated 95% confidence interval (CI). The meta-analyses were conducted using the random-effect model. P values < 0.05 were considered statistically significant. Subgroup analyses of all primary and secondary outcomes were performed only in women aged 35-40 years.
resultsTwelve studies were identified. In women aged between 35 and 40 years, r-hFSH/r-hLH co-treatment was associated with higher clinical pregnancy rates (OR 1.45, CI 95% 1.05-2.00, I
conclusionAlthough more oocytes were retrieved in patients who underwent r-hFSH monotherapy, this meta-analysis suggests that r-hFSH/r-hLH co-treatment improves clinical pregnancy and implantation rates in women between 35 and 40 years of age undergoing ovarian stimulation for assisted reproduction technology. However, more RCTs using narrower age ranges in advanced age women are warranted to corroborate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.